These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12489365)

  • 1. FDA reporting program is key to safety information.
    Young D
    Am J Health Syst Pharm; 2002 Dec; 59(23):2279, 2284, 2289. PubMed ID: 12489365
    [No Abstract]   [Full Text] [Related]  

  • 2. MedWatch. FDA's 'heads up' on medical product safety.
    Henkel J
    FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
    [No Abstract]   [Full Text] [Related]  

  • 3. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 7. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 8. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting to the FDA.
    Dippel JV
    RN; 1993 Dec; 56(12):61-2. PubMed ID: 8265993
    [No Abstract]   [Full Text] [Related]  

  • 13. The prescription drug user fee act: active postmarketing drug surveillance and safety.
    Lyles A
    Clin Ther; 2002 May; 24(5):800-2. PubMed ID: 12075947
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 16. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 17. MedWatch program.
    White GG
    Int J Trauma Nurs; 1998; 4(3):100-3. PubMed ID: 9855977
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 20. ORA's role at FDA headquarters and in the field for product recalls.
    Whetstone SN
    Food Drug Law J; 1998; 53(3):513-6. PubMed ID: 10346723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.